Effects of Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting on Clinical Outcomes in Patients with Reduced Ejection Fraction Heart Failure and Coronary Heart Disease: A Meta-Analysis
DOI:
https://doi.org/10.1532/hsf.5169Keywords:
coronary heart disease (CHD), reduced ejection fraction heart failure (HFrEF), PCI, CABG, major adverse cardiovascular events (MACE)Abstract
Objective: To clarify the effects of percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) on the clinical outcomes of patients with coronary heart disease (CHD) complicated with reduced ejection fraction heart failure (HFrEF) through meta-analysis.
Methods: Three major literature databases – PubMed, Web of Science, and Cochrane – were searched by search terms and the literature retrieval time was publications dating from January 2007 to December 2021. To search for observational studies and randomized controlled trials (RCT) comparing the efficacy of PCI and CABG in patients with CHD and HFrEF, the abstract or full text of the literature was read and the final included literature was determined, according to inclusion and exclusion criteria. The quality of the included literature was evaluated using the Ottawa scale and data extraction was further completed. Data analysis was made using RevMan5.4 and R4.1 software; relevant forest plots and funnel plots were made, according to the extracted data. Egger’s test was used to evaluate whether the data had publication bias. Outcomes were the major adverse cardiovascular events (MACE).
Results: A total of 10 studies were included and 11,032 subjects were included, made up of 5,521 cases of PCI and 5,511 cases of CABG. The results showed no significant difference between the two groups in cardiac mortality (CM) (RR=1.13, 95% CI 0.98-1.30, P = 0.10) and in overall all-cause mortality (ACM) (RR=1.12, 95% CI 0.92-1.37, P = 0.25). In the subgroup analysis of ACM, in the subgroups with left ventricular ejection fraction (LVEF) less than 35% and exceeding 35% and less than 50% (RR=1.12, 95% CI 0.92-1.37, P = 0.25) between the two groups, there was no statistical difference. However, among other MACE, compared with the PCI group, the CABG group had a lower risk of MACE (RR=1.58, 95%CI 1.49-1.70, P < 0.00001), myocardial infarction (MI) (RR=1.99, 95% CI 1.02-3.88, P = 0.04), heart failure (HF) (RR=1.29, 95% CI 1.17-1.43, P < 0.00001) and revascularization (RR=2.74, 95% CI 1.93-3.90, P < 0.00001). Finally in the CABG group, the risk of stroke or transient ischemic attack (TIA) was higher (RR=0.71, 95% CI 0.58-0.86, P = 0.0006) than the PCI group.
Conclusions: The mortality rates of PCI and CABG were similar in patients with CHD complicated with HFrEF. Compared with PCI, CABG had a lower incidence of MACE, MI, HF, and revascularization, and a higher incidence of stroke or TIA.
References
Bangalore S, Guo Y, Samadashvili Z, Blecker S, Hannan EL. 2016. Revascularization in patients with multivessel coronary artery disease and severe left ventricular systolic dysfunction: everolimus-eluting stents versus coronary artery bypass graft surgery. Circulation. 133:2132-40.
Bianco V, Kilic A, Mulukutla S, et al. 2021. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with reduced ejection fraction. J Thorac Cardiovasc Surg. 161:1022-31.
Brophy TJ, Warsavage TJ, Hebbe AL, et al. 2021. Percutaneous coronary intervention in patients with stable coronary artery disease and left ventricular systolic dysfunction: insights from the VA CART program. Am Heart J. 235:149-57.
China Cardiovascular Health and Disease Report 2020. 2021. Journal of Cardiovascular and Pulmonary Diseases. 40:885-9.
Cui K, Zhang D, Lyu S, et al. 2018. Meta-Analysis Comparing percutaneous coronary revascularization using drug-eluting stent versus coronary artery bypass grafting in patients with left ventricular systolic dysfunction. Am J Cardiol. 122:1670-6.
Fukui T, Tabata M, Takanashi S. 2014. Long-term outcomes after off-pump coronary artery bypass grafting in left ventricular dysfunction. Ann Thorac Cardiovasc Surg. 20:143-9.
GBD 2017 DALYs and HALE Collaborators. 2018. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017 (published correction appears in Lancet. 2019 Jun 22;393(10190): e44). Lancet. 392:1859-922.
Gioia G, Matthai W, Gillin K, et al. 2007. Revascularization in severe left ventricular dysfunction: outcome comparison of drug-eluting stent implantation versus coronary artery by-pass grafting. Catheter Cardiovasc Interv. 70:26-33.
Kang SH, Lee CW, Baek S, et al. 2017. Comparison of outcomes of coronary artery bypass grafting versus drug-eluting stent implantation in patients with severe left ventricular dysfunction. Am J Cardiol. 120:69-74.
Khan MR, Kayani WT, Pelton J, et al. 2021. Coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular systolic dysfunction. Cardiovasc Drugs Ther. 35:575-85.
Kunadian V, Pugh A, Zaman AG, Qiu W. 2012. Percutaneous coronary intervention among patients with left ventricular systolic dysfunction: a review and meta-analysis of 19 clinical studies. Coron Artery Dis. 23:469-79.
Maile MD, Mathis MR, Habib RH, Schwann TA, Engoren MC. 2021. Association of both high and low left ventricular ejection fraction with increased risk after coronary artery bypass grafting. Heart Lung Circ. 30:1091-9.
Marui A, Kimura T, Nishiwaki N, et al. 2014. CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Comparison of five-year outcomes of coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular ejection fractions ≤50% versus >50% (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). Am J Cardiol. 114:988-96.
Mestres CA, Van Hemelrijck M, Sromicki J. 2021. Coronary artery bypass grafting is superior to percutaneous coronary intervention in patients with left ventricular dysfunction. J Card Surg. 36:3843-5.
Nagendran J, Norris CM, Graham MM, et al. 2013. APPROACH Investigators. Coronary revascularization for patients with severe left ventricular dysfunction. Ann Thorac Surg. 96:2038-44.
Park S, Ahn JM, Kim TO, et al. 2020. IRIS-MAIN Registry Investigators. Revascularization in patients with left main coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol. 76:1395-1406.
Ponikowski P, Voors AA, Anker SD, et al. 2016. Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 18:891-975.
Shah S, Benedetto U, Caputo M, Angelini GD, Vohra HA. 2019. Comparison of the survival between coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with poor left ventricular function (ejection fraction <30%): a propensity-matched analysis. Eur J Cardiothorac Surg. 55:238-46.
Shen LL, Wang R, Gao CQ, et al. 2016. Different approaches to revascularization for complex coronary artery disease and left ventricular dysfunction: analysis of perioperative outcomes. Nan Fang Yi Ke Da Xue Bao. 36:327-31.
Sun LY, Gaudino M, Chen RJ, Bader Eddeen A, Ruel M. 2020. Long-term outcomes in patients with severely reduced left ventricular ejection fraction undergoing percutaneous coronary intervention vs coronary artery bypass grafting. JAMA Cardiol. 5:631-41.
Tribak M, Konaté M, Saidi S, et al. 2022. Pontage coronaire chez les patients en dysfonction systolique sévère du ventricule gauche: résultats à court et à long terme [Coronary artery bypass grafting in patients with severe left ventricular systolic dysfunction: Short- and long-term outcomes]. Ann Cardiol Angeiol (Paris). 71:11-6.
Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses.
Yang JH, Choi SH, Song YB, et al. 2013. Long-term outcomes of drug-eluting stent implantation versus coronary artery bypass grafting for patients with coronary artery disease and chronic left ventricular systolic dysfunction. Am J Cardiol. 112:623-9.
Yee NP, Siu AM, Davis J, Kao J. 2016. Recovery of left ventricular function after percutaneous coronary intervention compared to coronary artery bypass grafting in patients with multi-vessel coronary disease and left ventricular dysfunction. Hawaii J Med Public Health. 75:273-7.
Yokoyama Y, Fukuhara S, Mori M, et al. 2021. Network meta-analysis of treatment strategies in patients with coronary artery disease and low left ventricular ejection fraction. J Card Surg. 36:3834-42.
Yu HY, Park YS, Son YJ. 2017. Combined effect of left ventricular ejection fraction and post-cardiac depressive symptoms on major adverse cardiac events after successful primary percutaneous coronary intervention: A 12-month follow-up. Eur J Cardiovasc Nurs. 16:37-45.
Zhang D, Lyu S, Song X, et al. 2017. Coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular systolic dysfunction: A meta-analysis. Angiology. 68:19-28.
Zhang H, Shi R, Qin W, et al. 2021. Mid-term outcomes of coronary artery bypass grafting in patients with mild left ventricular systolic dysfunction: A multicentre retrospective cohort study. Interact Cardiovasc Thorac Surg. 32:855-63.
